Compare MIRM & ENPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | ENPH |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2019 | 2012 |
| Metric | MIRM | ENPH |
|---|---|---|
| Price | $64.32 | $32.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 23 |
| Target Price | ★ $87.55 | $42.02 |
| AVG Volume (30 Days) | 616.7K | ★ 6.6M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 233.44 |
| EPS | N/A | ★ 1.44 |
| Revenue | $471,794,000.00 | ★ $1,512,377,000.00 |
| Revenue This Year | $53.78 | $12.30 |
| Revenue Next Year | $19.91 | N/A |
| P/E Ratio | ★ N/A | $22.90 |
| Revenue Growth | ★ 53.66 | 20.97 |
| 52 Week Low | $36.88 | $25.78 |
| 52 Week High | $78.55 | $76.90 |
| Indicator | MIRM | ENPH |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 60.32 |
| Support Level | $63.66 | $26.42 |
| Resistance Level | $66.77 | $32.71 |
| Average True Range (ATR) | 2.99 | 1.30 |
| MACD | -0.69 | 0.74 |
| Stochastic Oscillator | 9.63 | 90.19 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.